
doi: 10.1002/dmrr.491
pmid: 15343582
AbstractThe chronic vascular complications of diabetes (nephropathy, retinopathy and accelerated atherosclerosis) are a major cause of morbidity and premature mortality. In spite of the more widespread availability of intensive diabetes management, approximately one in three people with diabetes develop aggressive complications and over 70% die of atherosclerosis‐related diseases. Genetic and acquired factors are likely to be contributory. Potential mediators of vascular damage may include the interrelated processes of lipoprotein abnormalities, glycation, oxidation and endothelial dysfunction. Lipoprotein abnormalities encompass alterations in lipid concentrations, lipoprotein composition and subclass distribution and lipoprotein‐related enzymes. Nonenzymatic glycation and oxidative damage to lipoproteins, other proteins and to vascular structures may also be deleterious. As atherosclerosis is a chronic condition commencing in youth, and because clinical events may be silent in diabetes, surrogate measures of vascular disease are important for early identification of diabetic patients with or at high risk of vascular damage, and for monitoring efficacy of interventions. The increasing array of biochemical assays for markers and mediators of vascular damage, noninvasive measures of vascular health, and therapeutic options should enable a reduction in the excessive personal and economic burden of vascular disease in type 1 and type 2 diabetes. Copyright © 2004 John Wiley & Sons, Ltd.
Glycation End Products, Advanced, Lipoproteins, 610, name=SDG 3 - Good Health and Well-being, Oxidative Stress, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, 616, Diabetes Mellitus, Glycosylation End Products, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Humans, Advanced, Type 2, Diabetic Angiopathies, Type 1
Glycation End Products, Advanced, Lipoproteins, 610, name=SDG 3 - Good Health and Well-being, Oxidative Stress, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, 616, Diabetes Mellitus, Glycosylation End Products, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, Humans, Advanced, Type 2, Diabetic Angiopathies, Type 1
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 93 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
